Abstract
Fifteen patients with advanced urothelial cancer were treated with carboplatin 300 mg/m2, methotrexate 30 mg/m2, and vinblastin 3 mg/m2 on day 1 and the same dosage of methotrexate and vinblastin on days 15 and 22. Six patients were pretreated with radiotherapy and or chemotherapy; 7 patients had impaired renal function due to obstructive uropathy. Eight patients achieved a partial remission; 4 patients achieved a minor remission or stabilization of progressive disease. Mean duration of response was 8+ month (2+ to 12+ month). Subjective tolerance of the treatment was excellent but there was considerable bone marrow toxicity in the pretreated patients. The data show that Carbo-MV (carboplatin, methotrexate, and vinblastin) is effective and subjectively well tolerated in advanced urothelial carcinoma.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carcinoma, Transitional Cell / mortality
-
Carcinoma, Transitional Cell / pathology
-
Carcinoma, Transitional Cell / therapy*
-
Combined Modality Therapy
-
Drug Evaluation
-
Female
-
Gastrointestinal Diseases / chemically induced
-
Gastrointestinal Diseases / epidemiology
-
Hematologic Diseases / chemically induced
-
Hematologic Diseases / epidemiology
-
Humans
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Staging
-
Radiotherapy / standards
-
Survival Rate
-
Urologic Neoplasms / mortality
-
Urologic Neoplasms / pathology
-
Urologic Neoplasms / therapy*
-
Vinblastine / administration & dosage
Substances
-
Vinblastine
-
Carboplatin
-
Methotrexate